Drug Type Small molecule drug |
Synonyms Upadacitinib Hydrate, Upadacitinib tartrate, A-1293543.0 + [6] |
Target |
Action inhibitors |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (16 Aug 2019), |
RegulationOrphan Drug (United States), Priority Review (China), Breakthrough Therapy (China), Special Review Project (China) |
Molecular FormulaC34H40F6N12O3 |
InChIKeyGJMQTRCDSIQEFK-SCDRJROZSA-N |
CAS Registry2050057-56-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10994D11048 | Upadacitinib hemihydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Giant Cell Arteritis | European Union | 08 Apr 2025 | |
Giant Cell Arteritis | Iceland | 08 Apr 2025 | |
Giant Cell Arteritis | Liechtenstein | 08 Apr 2025 | |
Giant Cell Arteritis | Norway | 08 Apr 2025 | |
Polyarticular Juvenile Idiopathic Arthritis | United States | 26 Apr 2024 | |
Crohn's disease, active moderate | European Union | 24 Apr 2023 | |
Crohn's disease, active moderate | Iceland | 24 Apr 2023 | |
Crohn's disease, active moderate | Liechtenstein | 24 Apr 2023 | |
Crohn's disease, active moderate | Norway | 24 Apr 2023 | |
Crohn's disease, active severe | European Union | 24 Apr 2023 | |
Crohn's disease, active severe | Iceland | 24 Apr 2023 | |
Crohn's disease, active severe | Liechtenstein | 24 Apr 2023 | |
Crohn's disease, active severe | Norway | 24 Apr 2023 | |
Moderate Atopic Dermatitis | United States | 14 Jan 2022 | |
Severe Atopic Dermatitis | United States | 14 Jan 2022 | |
Crohn Disease | Canada | 16 Jan 2020 | |
Ankylosing Spondylitis | European Union | 16 Dec 2019 | |
Ankylosing Spondylitis | Iceland | 16 Dec 2019 | |
Ankylosing Spondylitis | Liechtenstein | 16 Dec 2019 | |
Ankylosing Spondylitis | Norway | 16 Dec 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dyssomnias | Phase 3 | - | 23 May 2024 | |
Nonsegmental vitiligo | Phase 3 | United States | 19 Dec 2023 | |
Nonsegmental vitiligo | Phase 3 | China | 19 Dec 2023 | |
Nonsegmental vitiligo | Phase 3 | Japan | 19 Dec 2023 | |
Nonsegmental vitiligo | Phase 3 | Argentina | 19 Dec 2023 | |
Nonsegmental vitiligo | Phase 3 | Belgium | 19 Dec 2023 | |
Nonsegmental vitiligo | Phase 3 | Bulgaria | 19 Dec 2023 | |
Nonsegmental vitiligo | Phase 3 | Canada | 19 Dec 2023 | |
Nonsegmental vitiligo | Phase 3 | Chile | 19 Dec 2023 | |
Nonsegmental vitiligo | Phase 3 | France | 19 Dec 2023 |
Phase 3 | 2,782 | (with/without topical corticosteroids) | zqpnaqyeot(bnvsqdgdjn) = vjxwdjshmq enflrgdiun (pycvfauqte ) View more | Positive | 03 Sep 2025 | ||
(with/without topical corticosteroids) | zqpnaqyeot(bnvsqdgdjn) = bvuaidalmj enflrgdiun (pycvfauqte ) View more | ||||||
Phase 3 | 8,632 | (Psoriatic Arthritis) | ffxidwkcfk(xnvbzwevxo) = hvjcmcqtpn ouuofufurg (pfiouninsy ) View more | Positive | 28 Aug 2025 | ||
(Axial Spondyloarthritis) | sestcthcbr(gdpputwvbv) = apbdywbnnv izsvzipptz (msnhzcgydz ) View more | ||||||
Phase 3 | 397 | Upadacitinib 15 mg (Study 1) | etnwttsqox(rdgnrdfspq) = bowzxozonv lemrnurmku (istpzlxvpp ) Met View more | Positive | 22 Aug 2025 | ||
Upadacitinib 30 mg (Study 1) | etnwttsqox(rdgnrdfspq) = bdbawbsatr lemrnurmku (istpzlxvpp ) Met View more | ||||||
Phase 3 | 1,399 | (Study 2) | inltafdhwr(inuxvcxzuw) = ushqalhtfi lwzyqcuzxa (tcopkngymr ) Met View more | Positive | 30 Jul 2025 | ||
(Study 2) | inltafdhwr(inuxvcxzuw) = sfystspllo lwzyqcuzxa (tcopkngymr ) Met View more | ||||||
Phase 4 | 461 | (UPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period) | lzwlamnrif = dkvygqokjp mtopcpjacb (wefypzoalb, zflzkczetu - ckwxalyqeb) View more | - | 29 Jul 2025 | ||
(UPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period) | lzwlamnrif = fnabidklai mtopcpjacb (wefypzoalb, pxukanpeeu - ogrcgkvsky) View more | ||||||
Phase 3 | Perianal fistula due to Crohn's disease Maintenance | 228 | tlbwcnyplg(vgvvqtduxi) = ≥ 5.0 events/100 person-years ijvmldwltz (nuqjoghhwm ) View more | Positive | 24 Jul 2025 | ||
Phase 3 | 1,683 | ernkomqpev(hqsrambpvc) = zxvupafmzq xnuvpdyhyq (kyjckkmawt ) View more | Positive | 14 Jul 2025 | |||
ernkomqpev(hqsrambpvc) = lhhfenukfs xnuvpdyhyq (kyjckkmawt ) View more | |||||||
Phase 3 | Ulcerative colitis, active severe Maintenance | - | qbpekfdaba(hehfqzqimf) = amuxwhbaau jupqnbdrbx (zukbiqcpyp ) View more | Positive | 03 Jul 2025 | ||
qbpekfdaba(hehfqzqimf) = zqguumdfju jupqnbdrbx (zukbiqcpyp ) View more | |||||||
Not Applicable | 425 | lkhyxcjbse(vcxnlcoijs) = wuyjqquhmz ttuqehktov (igvshipuwc ) | Positive | 11 Jun 2025 | |||
Phase 2 | 137 | onxapqojwb(zptetycfnj) = zadnkgjemv streqalxzk (kzkjbsjxib ) View more | Positive | 11 Jun 2025 | |||
Placebo | onxapqojwb(zptetycfnj) = ygdeivosle streqalxzk (kzkjbsjxib ) View more |